Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Smoking Cessation and Nicotine Deaddiction – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Smoking Cessation and Nicotine Deaddiction: Overview
Nicotine is an extremely addictive chemical that is found in the tobacco plant. The addiction to nicotine is both physical and mental habitual users not only crave the chemical but also its effects. Using tobacco can lead to grave complications such as emphysema, lung cancer, stroke, chronic bronchitis, heart disease, and even eye-related conditions. Smoking cessation and nicotine deaddiction becomes imperative for improving the quality of life of people excessively dependent on nicotine.
“Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation and Nicotine Deaddiction pipeline landscape is provided which includes the disease overview and Smoking Cessation and Nicotine Deaddiction treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation and Nicotine Deaddiction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation and Nicotine Deaddiction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation and Nicotine Deaddiction R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation and Nicotine Deaddiction.
Smoking Cessation and Nicotine Deaddiction Emerging Drugs Chapters
This segment of the Smoking Cessation and Nicotine Deaddiction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Smoking Cessation and Nicotine Deaddiction Emerging Drugs
Cytisinicline: Achieve Life Sciences
The drug, Cytisinicline by Achieve Life Sciences is in the Phase III stage of drug development process for smoking withdrawal. The drug is now available for licensing. The drug’s dual acting mechanism of action exclusively targets the alpha-4-beta-2 nicotine receptor. It is believed to curb nicotine craving and withdrawal symptoms.
NFL 101: NFL Biosciences
NFL Biosciences’ drug candidate NFL 101 is in the Phase II stage of drug development. According to the observations made in the clinical trial, the drug helped in reducing nicotine dependence in cigarette smokers.
Further product details are provided in the report……..
Smoking Cessation and Nicotine Deaddiction: Therapeutic Assessment
This segment of the report provides insights about the different Smoking Cessation and Nicotine Deaddiction drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Smoking Cessation and Nicotine Deaddiction
There are approx. 5+ key companies which are developing the therapies for Smoking Cessation and Nicotine Deaddiction. The companies which have their Smoking Cessation and Nicotine Deaddiction drug candidates in the mid to advanced stage, i.e. phase III include, Achieve Life Sciences and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Smoking Cessation and Nicotine Deaddiction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Smoking Cessation and Nicotine Deaddiction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation and Nicotine Deaddiction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation and Nicotine Deaddiction drugs.
Smoking Cessation and Nicotine Deaddiction Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Smoking Cessation and Nicotine Deaddiction – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Smoking Cessation and Nicotine Deaddiction: Overview
Nicotine is an extremely addictive chemical that is found in the tobacco plant. The addiction to nicotine is both physical and mental habitual users not only crave the chemical but also its effects. Using tobacco can lead to grave complications such as emphysema, lung cancer, stroke, chronic bronchitis, heart disease, and even eye-related conditions. Smoking cessation and nicotine deaddiction becomes imperative for improving the quality of life of people excessively dependent on nicotine.
“Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation and Nicotine Deaddiction pipeline landscape is provided which includes the disease overview and Smoking Cessation and Nicotine Deaddiction treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation and Nicotine Deaddiction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation and Nicotine Deaddiction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation and Nicotine Deaddiction R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation and Nicotine Deaddiction.
Smoking Cessation and Nicotine Deaddiction Emerging Drugs Chapters
This segment of the Smoking Cessation and Nicotine Deaddiction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Smoking Cessation and Nicotine Deaddiction Emerging Drugs
Cytisinicline: Achieve Life Sciences
The drug, Cytisinicline by Achieve Life Sciences is in the Phase III stage of drug development process for smoking withdrawal. The drug is now available for licensing. The drug’s dual acting mechanism of action exclusively targets the alpha-4-beta-2 nicotine receptor. It is believed to curb nicotine craving and withdrawal symptoms.
NFL 101: NFL Biosciences
NFL Biosciences’ drug candidate NFL 101 is in the Phase II stage of drug development. According to the observations made in the clinical trial, the drug helped in reducing nicotine dependence in cigarette smokers.
Further product details are provided in the report……..
Smoking Cessation and Nicotine Deaddiction: Therapeutic Assessment
This segment of the report provides insights about the different Smoking Cessation and Nicotine Deaddiction drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Smoking Cessation and Nicotine Deaddiction
There are approx. 5+ key companies which are developing the therapies for Smoking Cessation and Nicotine Deaddiction. The companies which have their Smoking Cessation and Nicotine Deaddiction drug candidates in the mid to advanced stage, i.e. phase III include, Achieve Life Sciences and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Smoking Cessation and Nicotine Deaddiction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Smoking Cessation and Nicotine Deaddiction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation and Nicotine Deaddiction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation and Nicotine Deaddiction drugs.
Smoking Cessation and Nicotine Deaddiction Report Insights
- Smoking Cessation and Nicotine Deaddiction Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Smoking Cessation and Nicotine Deaddiction drugs?
- How many Smoking Cessation and Nicotine Deaddiction drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smoking Cessation and Nicotine Deaddiction?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation and Nicotine Deaddiction therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Smoking Cessation and Nicotine Deaddiction and their status?
- What are the key designations that have been granted to the emerging drugs?
- Achieve LifeSciences
- NFL Biosciences
- Axsome Therapeutics
- Cytisinicline
- NFL 101
- AXS-05
Introduction
Executive Summary
Smoking Cessation and Nicotine Deaddiction: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Smoking Cessation and Nicotine Deaddiction – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Smoking Cessation and Nicotine Deaddiction companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Smoking Cessation and Nicotine Deaddiction Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Cytisinicline: Achieve Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NFL 101: NFL Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Smoking Cessation and Nicotine Deaddiction Key Companies
Smoking Cessation and Nicotine Deaddiction Key Products
Smoking Cessation and Nicotine Deaddiction- Unmet Needs
Smoking Cessation and Nicotine Deaddiction- Market Drivers and Barriers
Smoking Cessation and Nicotine Deaddiction- Future Perspectives and Conclusion
Smoking Cessation and Nicotine Deaddiction Analyst Views
Smoking Cessation and Nicotine Deaddiction Key Companies
Appendix
Executive Summary
Smoking Cessation and Nicotine Deaddiction: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Smoking Cessation and Nicotine Deaddiction – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Smoking Cessation and Nicotine Deaddiction companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Smoking Cessation and Nicotine Deaddiction Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Cytisinicline: Achieve Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NFL 101: NFL Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Smoking Cessation and Nicotine Deaddiction Key Companies
Smoking Cessation and Nicotine Deaddiction Key Products
Smoking Cessation and Nicotine Deaddiction- Unmet Needs
Smoking Cessation and Nicotine Deaddiction- Market Drivers and Barriers
Smoking Cessation and Nicotine Deaddiction- Future Perspectives and Conclusion
Smoking Cessation and Nicotine Deaddiction Analyst Views
Smoking Cessation and Nicotine Deaddiction Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Smoking Cessation and Nicotine Deaddiction
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Smoking Cessation and Nicotine Deaddiction
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Smoking Cessation and Nicotine Deaddiction
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Smoking Cessation and Nicotine Deaddiction
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
